20.75
0.74 (3.70%)
| Penutupan Terdahulu | 20.01 |
| Buka | 20.62 |
| Jumlah Dagangan | 1,197,014 |
| Purata Dagangan (3B) | 1,554,316 |
| Modal Pasaran | 2,347,513,856 |
| Harga / Jualan (P/S) | 252.07 |
| Harga / Buku (P/B) | 3.57 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2026 |
| Margin Operasi (TTM) | -1,525.50% |
| EPS Cair (TTM) | -3.01 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 184.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.55% |
| Nisbah Semasa (MRQ) | 10.49 |
| Aliran Tunai Operasi (OCF TTM) | -152.68 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -117.16 M |
| Pulangan Atas Aset (ROA TTM) | -33.54% |
| Pulangan Atas Ekuiti (ROE TTM) | -69.21% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Immunome, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | 4.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.70 |
|
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 11.48% |
| % Dimiliki oleh Institusi | 83.28% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Enavate Sciences Gp, Llc | 31 Dec 2025 | 4,768,583 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 40.00 (HC Wainwright & Co., 92.77%) | Beli |
| Median | 33.50 (61.45%) | |
| Rendah | 30.00 (Stephens & Co., 44.58%) | Beli |
| Purata | 34.25 (65.06%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 22.58 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Craig-Hallum | 04 Mar 2026 | 36.00 (73.49%) | Beli | 22.52 |
| Stephens & Co. | 04 Mar 2026 | 30.00 (44.58%) | Beli | 22.52 |
| HC Wainwright & Co. | 12 Feb 2026 | 40.00 (92.77%) | Beli | 22.44 |
| Wedbush | 15 Jan 2026 | 31.00 (49.40%) | Beli | 22.85 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Feb 2026 | Pengumuman | Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 04 Feb 2026 | Pengumuman | Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 |
| 08 Jan 2026 | Pengumuman | Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 06 Jan 2026 | Pengumuman | Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |